HOME2019-03-11T17:27:49+00:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Public Event for Parkinson’s Awareness Month 2020

February 17th, 2020|

To mark Parkinson's Awareness Month 2020, RCSI are hosting an event about the state-of-the-art Parkinson's research in Ireland. Perspectives from research laboratories, the clinic, industry and those with the condition will be shared through short, lively talks followed by a Q&A session. Talks will be followed by a reception and [...]

PD-MitoQUANT publishes its second newsletter

February 3rd, 2020|

Happy New Year to all who are following the progress of PD-MitoQUANT. We are pleased to provide you with our latest project update. Please find our January 2020 newsletter for download here.  

Read the latest PD-MitoQUANT-acknowledged publication co-authored by our PIs at CNRS

January 20th, 2020|

Congratulations to all authors involved in the latest PD-MitoQUANT-acknowledged publication: Nolwen L. Rey, Luc Bousset, Sonia George, Zachary Madaj, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Ronald Melki and Patrik Brundin. PD-MitoQUANT PIs Luc Bousset and Ronald Melki are researchers at the Centre National de la Recherche Scientifique (CNRS). The [...]

Read more